



Neuland Q2FY26 Total income at Rs.516.1 crore; EBITDA at Rs.156.9 crore

Hyderabad, India, Nov 7, 2025 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the half year ended Sep 30th, 2025.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *“Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”*

Financial Summary

Rs. crore					
Particulars (Rs Cr)	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)
Total Income	516.1	315.2	63.70%	300.6	71.70%
EBITDA	156.9	65.7	138.80%	42.1	272.70%
EBITDA Margin	30.40%	20.80%	960 bps	14.00%	1640 bps
Exceptional Item*	-	-	-	-	-
Profit Before Tax*	129.0	48.5	166.00%	17.4	641.40%
PBT Margin	25.00%	15.40%	960 bps	5.79%	1921 bps
Profit After Tax	96.5	32.0	201.60%	13.7	604.40%

Q2 FY26 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST** on **Friday, Nov 7, 2025** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 995 Regulatory filings across the US (73 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com